A5102986971- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Peripheral Artery Disease Management
- Cerebrovascular and Carotid Artery Diseases
- Aortic aneurysm repair treatments
- Atrial Fibrillation Management and Outcomes
- Integrated Circuits and Semiconductor Failure Analysis
- Venous Thromboembolism Diagnosis and Management
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Vascular Procedures and Complications
- Blood Pressure and Hypertension Studies
- Advancements in Photolithography Techniques
- Lipoproteins and Cardiovascular Health
- Cardiac Structural Anomalies and Repair
- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Central Venous Catheters and Hemodialysis
- Cardiovascular Health and Disease Prevention
- Optical Coherence Tomography Applications
- Public Administration and Political Analysis
- Cardiovascular Health and Risk Factors
Mitsui Memorial Hospital
2016-2025
Municipal Hirakata City Hospital
2024
Japanese Red Cross Society Wakayama Medical Center
2023
Memorial Hospital
2023
Ollscoil na Gaillimhe – University of Galway
2023
European Society of Cardiology
2023
St. Marianna University School of Medicine
2023
Clinical Research Consortium
2021
Lenox Hill Hospital
2021
Stanford University
2021
<h3>Importance</h3> Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option. <h3>Objective</h3> To test the hypothesis of noninferiority 1 month DAPT compared standard 12 months for composite end point cardiovascular and bleeding events. <h3>Design, Setting, Participants</h3> Multicenter, open-label, randomized clinical trial enrolling 3045 patients who underwent PCI at 90 hospitals in Japan...
The effectiveness of sirolimus-eluting stents in unselected patients treated the daily practice is currently unknown.Sirolimus-eluting stent implantation has been used as default strategy for all percutaneous procedures our hospital part Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Consecutive with de novo lesions (n=508) exclusively (SES group) were compared 450 who received bare period just before (pre-SES group). Patients SES group more...
Theoretically, bioresorbable vascular scaffolds (BVSs) may provide superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective DESs prior to complete bioresorption is unknown. ABSORB Japan was a single-blind, multicentre, active-controlled, randomized trial designed support regulatory approval of the Absorb BVS in Japan. Eligible patients one or two de novo lesions different epicardial vessels were at 38 Japanese...
<h3>Importance</h3> Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute syndrome (ACS). <h3>Objective</h3> To test the hypothesis of noninferiority 1 to 2 months DAPT compared 12 for a composite end point cardiovascular and bleeding events ACS. <h3>Design, Setting, Participants</h3> This multicenter, open-label, randomized clinical trial enrolled 4169 ACS who underwent...
The goal of this intravascular ultrasound investigation was to provide a more detailed morphological analysis the local biological effects implantation sirolimus-eluting stent compared with an uncoated stent.In RAVEL trial, 238 patients single de novo lesions were randomized receive either 18-mm (Bx VELOCITY stent, Cordis) or stent). In subset 95 (sirolimus-eluting stent=48, stent=47), motorized pullback (0.5 mm/s) performed at 6-month follow-up. Stent volumes, total vessel and...
The first clinical study of paclitaxel-eluting stent for de novo lesions showed promising results. We performed the TAXUS III trial to evaluate feasibility and safety treatment in-stent restenosis (ISR).The was a single-arm, 2-center that enrolled 28 patients with ISR meeting criteria lesion length < or =30 mm, 50% 99% diameter stenosis, vessel 3.0 3.5 mm. They were treated one more NIRx stents. Twenty-five completed angiographic follow-up at 6 months, 17 these underwent intravascular...
We describe the clinical and morphological patterns of restenosis after sirolimus-eluting stent (SES) implantation.From 121 patients with coronary angiography obtained >30 days SES implantation, (diameter stenosis >50%) was identified in 19 20 lesions (located at proximal 5-mm segment 30% or within 70%). Residual dissection procedure balloon trauma outside 83% edge lesions. Lesions were focal, discontinuity some evaluated by intravascular ultrasound.Sirolimus-eluting is frequently associated...
Restenosis remains the major limitation of coronary catheter-based intervention. In small vessels, amount neointimal tissue is disproportionately greater than vessel caliber, resulting in higher restenosis rates. Randomized Study With Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, approximately 40% vessels were (<2.5 mm). The present study evaluates relationship between angiographic outcome and diameter for sirolimus-eluting stents.Patients randomized to receive either...
NEXT (NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial) was designed for evaluating the noninferiority of a biolimus-eluting stent (BES) relative to an everolimus-eluting (EES) in terms target lesion revascularization (TLR) at 1 year.Efficacy and safety data comparing biodegradable polymer BES with durable cobalt-chromium EES are currently limited.The trial is prospective, multicenter, randomized, open-label, EES. Between May October 2011, 3,235 patients were...
Early results of sirolimus-eluting stent implantation showed a nearly complete abolition neointimal hyperplasia. The question remains, however, whether the early promising will still be evident at long-term follow-up. objective our study was to evaluate efficiency for up 2 years follow-up.Fifteen patients with de novo coronary artery disease were treated 18-mm Bx-Velocity stents (Cordis) loaded 140 microg sirolimus/cm2 metal surface area in slow release formulation. Quantitative angiography...
Abstract Background : Stent fracture is one of the possible causes restenosis after sirolimus‐eluting stents (SES) implantation. The aim our study was to evaluate prevalence and clinical impact coronary stent SES Methods From prospective institutional database, 280 patients were treated solely with from August 2004 June 2005. Among patients, 256 a total 307 lesions underwent follow‐up angiography on an average 240 days procedure. Results fractures observed in eight (2.6%) lesions. Of...
Background— The clinical impact of late incomplete stent apposition (ISA) for drug-eluting stents is unknown. We sought to prospectively investigate the incidence and extent ISA after procedure at 6-month follow-up paclitaxel-eluting in comparison with bare metal (BMS) survey significance over a period 12 months. Methods Results— TAXUS II was randomized, double-blind study 536 patients 2 consecutive cohorts comparing slow-release (SR; 131 patients) moderate-release (MR; 135 BMS (270...
Background— Several recent randomized trials comparing everolimus-eluting stent (EES) and sirolimus-eluting (SES) reported similar outcomes. However, only 1 trial was powered for a clinical end point, no evaluating target-lesion revascularization. Methods Results— Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting Trial is prospective multicenter open-label EES with SES in Japan. The noninferiority relative to terms From February July 2010, 3197 patients were randomly...
We sought to investigate two-year clinical and serial optical coherence tomography (OCT) outcomes after implantation of a fully bioresorbable vascular scaffold (BVS) or cobalt-chromium everolimus-eluting stent (CoCr-EES).In the ABSORB Japan trial, 400 patients were randomised in 2:1 ratio BVS (N=266) CoCr-EES (N=134). A pre-specified OCT subgroup (N=125, OCT-1 group) underwent angio-graphy post procedure at two years. Overall, TLF rates 7.3% 3.8% arms (p=0.18), respectively. Very late...
Abstract Quantitative coronary angiography (QCA) remains to play an important role in clinical trials and post-marketing surveillance related the safety efficacy of new PCI devices. In this document, current standard methodology QCA is summarized. addition, its history, recent development future perspectives are also reviewed.
Background Scarce data exist about the outcomes after percutaneous coronary intervention ( PCI ) in old patients. This study sought to provide an overview of elderly patients, especially nonagenarians, a Japanese large prospective nationwide registry. Methods and Results We analyzed 562 640 patients undergoing (≥60 years age) from 1018 hospitals between 2014 2016 J-PCI (Japanese intervention) Among them, 10 628 (1.9%), including 6780 (1.2%) with acute syndrome ACS 3848 (0.7%) stable artery...
Aims: We aimed to evaluate the validity of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria East Asian patients undergoing contemporary percutaneous coronary intervention (PCI) from PENDULUM registry.
Incomplete stent apposition (ISA) has been previously documented after sirolimus-eluting (SES) implantation. The aim of this study was to investigate the long-term intravascular ultrasound (IVUS) findings ISA in patients who received SES.A total 13 SES and showed at follow-up IVUS (follow-up I) were investigated. performed on all these 12 months later II). Quantitative area measurement also I II. No vascular remodeling observed vessel segment with ISA; external elastic membrane 19.4+/-6.6...